Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, Stavudine, Amprenavir/Ritonavir, Protease Inhibitors, Lamivudine, VX 478, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load, Abacavir Sulfate, Acute Infection, Treatment Interruption
Eligibility Criteria
Inclusion Criteria: Acute HIV infection (recently infected with HIV or recent seroconversion) Karnofsky status of 80 or greater within 14 days prior to study entry Acceptable methods of contraception Able and willing to give written informed consent Exclusion Criteria: Previously received anti-HIV drugs Hepatitis within 30 days prior to study entry Pancreatitis within 120 days prior to study entry Radiation or chemotherapy within 30 days prior to study entry Certain medications within 14 days prior to study entry Experimental or investigational therapy within 30 days prior to study entry Illness (non-HIV infection, cancer, etc.) at the time of study entry Pregnant or breastfeeding
Sites / Locations
- USC CRS
- UCLA CARE Center CRS
- Ucsd, Avrc Crs
- Ucsf Aids Crs
- University of Colorado Hospital CRS
- Univ. of Hawaii at Manoa, Leahi Hosp.
- Massachusetts General Hospital ACTG CRS
- SSTAR, Family Healthcare Ctr.
- Washington U CRS
- Beth Israel Med. Ctr. ACTU
- NY Univ. HIV/AIDS CRS
- Columbia P&S CRS
- AIDS Care CRS
- McCree McCuller Wellness Ctr. at the Connection, Infectious Disease Unit
- Univ. of Rochester ACTG CRS
- Unc Aids Crs
- Hosp. of the Univ. of Pennsylvania CRS
- The Miriam Hosp. ACTG CRS